16/06/2021

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

The efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia are unclear.

Matéria Original

Anterior

Molecular insight into the genomic variation of SARS-CoV-2 strains from current outbreak
Próxima

Computational drug repurposing study of antiviral drugs against main protease, RNA polymerase, and spike proteins of SARS-CoV-2 using molecular docking method